Development
Lexicon Pharmaceuticals, Inc.
LXRX
$1.05
-$0.07-6.25%
NASDAQ
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | 531.00K | 408.00K | 126.00K | 139.00K | 125.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 531.00K | 408.00K | 126.00K | 139.00K | 125.00K |
| Cost of Revenue | 58.12M | 51.11M | 49.92M | 52.82M | 55.34M |
| Gross Profit | -57.59M | -50.70M | -49.79M | -52.68M | -55.21M |
| SG&A Expenses | 97.71M | 78.05M | 58.73M | 48.08M | 40.60M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 155.82M | 129.16M | 108.65M | 100.90M | 95.94M |
| Operating Income | -155.29M | -128.76M | -108.52M | -100.76M | -95.81M |
| Income Before Tax | -157.86M | -130.72M | -110.40M | -101.94M | -97.06M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -157.86 | -130.72 | -110.40 | -101.94 | -97.06 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -157.86M | -130.72M | -110.40M | -101.94M | -97.06M |
| EBIT | -155.29M | -128.76M | -108.52M | -100.76M | -95.81M |
| EBITDA | -154.78M | -128.29M | -108.09M | -100.33M | -95.38M |
| EPS Basic | -0.76 | -0.68 | -0.63 | -0.62 | -0.63 |
| Normalized Basic EPS | -0.47 | -0.43 | -0.39 | -0.39 | -0.39 |
| EPS Diluted | -0.76 | -0.68 | -0.63 | -0.62 | -0.63 |
| Normalized Diluted EPS | -0.47 | -0.43 | -0.39 | -0.39 | -0.39 |
| Average Basic Shares Outstanding | 827.45M | 757.43M | 702.26M | 662.40M | 622.57M |
| Average Diluted Shares Outstanding | 827.45M | 757.43M | 702.26M | 662.40M | 622.57M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |